Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Abstract Background Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and LDL particle number (LDL-PN). The pre...

Full description

Bibliographic Details
Main Authors: Kausik K. Ray, Stefano Del Prato, Dirk Müller-Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Jonas Mandel, Rita Samuel, Maja Bujas-Bobanovic, Lawrence A. Leiter
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Cardiovascular Diabetology
Subjects:
Alirocumab
Atherosclerotic cardiovascular disease
Type 2 diabetes mellitus
Low-density lipoprotein cholesterol
Dyslipidemia
Online Access:http://link.springer.com/article/10.1186/s12933-019-0951-9

Internet

http://link.springer.com/article/10.1186/s12933-019-0951-9

Similar Items